Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissuesICD-10-CM
No Prior Auth Required
Covered without prior authorization (high confidence)
CGS-J15-L34037, Flow Cytometry
J15
CGS-J15-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J15
CGS-J18-L34037, Flow Cytometry
J18
CGS-J18-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J18
WPS-J5-L38835, MolDX: Minimal Residual Disease Testing for Cancer
J5
A59004, Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
J5
A58756, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
WPS-J5-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
A59915, Billing and Coding: Pharmacogenomic Testing
J6
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
NGS-J6-L39995, Pharmacogenomic Testing
J6
A59101, Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
J6
WPS-J8-L38835, MolDX: Minimal Residual Disease Testing for Cancer
J8
WPS-J8-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J8
A58812, Billing and Coding: Pharmacogenomics Testing
J9
FIRST_COAST-L39073, Pharmacogenomics Testing
J9
NOVITAS-JH-L39063, Pharmacogenomics Testing
JH
NGS-JK-L39995, Pharmacogenomic Testing
JK
NGS-JK-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
JK
NOVITAS-JL-L39063, Pharmacogenomics Testing
JL
Ask Backwork about documentation requirements, denial risks, or coverage in your state.